Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults.
Scaggs Huang, F; Bernstein, DI; Slobod, KS; Portner, A; Takimoto, T; Russell, CJ; Meagher, M; Jones, BG; Sealy, RE; Coleclough, C; et al.
Human Vaccines and Immunotherapeutics.
2021;
17:554-559.
Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
Clarkson, KA; Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Weerts, HP; Heaney, CD; McNeal, M; Detizio, K; Parker, S; et al.
mSphere.
2020;
5.
Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G.
Frenck, RW; Dickey, M; Suvarnapunya, AE; Chandrasekaran, L; Kaminski, RW; Clarkson, KA; McNeal, M; Lynen, A; Parker, S; Hoeper, A; et al.
mSphere.
2020;
5.
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.
Bernstein, DI; Guptill, J; Naficy, A; Nachbagauer, R; Berlanda-Scorza, F; Feser, J; Wilson, PC; Solorzano, A; Van der Wielen, M; Walter, EB; et al.
The Lancet Infectious Diseases.
2020;
20:80-91.
A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
Bernstein, DI; Pasetti, MF; Brady, R; Buskirk, AD; Wahid, R; Dickey, M; Cohen, M; Baughman, H; El-Khorazaty, J; Maier, N; et al.
Vaccine.
2019;
37:602-611.
A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.
Jr, FR W; Baqar, S; Alexander, W; Dickey, M; McNeal, M; El-Khorazaty, J; Baughman, H; Hoeper, A; Barnoy, S; Suvarnapunya, AE; et al.
Vaccine.
2018;
36:4880-4889.